Atypical fractures associated with the long term use of bisphosphonates. The current situation;Fracturas atípicas relacionadas con el uso prolongado de bifosfonatos. Estado de la situación

Revista Espanola de Cirugia Ortopedica y Traumatologia

Volumn 55, Issue 5, 2011, Pages 392-404

  Caeiro Rey, J R ^a,d   Etxebarria Foronda, I ^b,d   Mesa Ramos, M ^c,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Hospital Alto Deba   (Spain)

^c Hospital Valle de los Pedroches   (Spain)

^d GEIOS ^*  (Spain)

Author keywords

Atypical fractures; Bisphosphonates; Diaphyseal femur fractures; Insufficiency fractures; Stress fractures; Subtrochanteric fractures

Indexed keywords

EID: 80052181815     PISSN: 18884415     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.recot.2011.05.002     Document Type: Short Survey

References (46)

1. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Rev Osteoporos Metab Miner 2009, 1:53-60. Comité de expertos de la SEIOMM.
2. González-Macías J., Guañabens Gay N., Gómez Alonso C., del Río Barquero L., Muñoz-Torres M., Delgado M., et al. Guías de Práctica Clínica en la Osteoporosis Postmenopáusica, Glucocorticoidea y del Varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral. Rev Clin Esp 2008, Suppl 1:S1-S24. en representación del Comité de Expertos de la SEIOMM para la elaboración de las Guías.
3. Ott S.M. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab 2001, 86:1835.
4. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
5. Lee P., van der Wall H., Seibel M.J. Looking beyond low bone mineral density: Multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007, 30:590-597.
6. Sayed-Noor A.S., Sjöden G.O. Subtrochanteric displaced insufficiency fracture after lon-term alendronate therapy. A case report. Acta Orthop 2008, 79:565-567.
7. Wernecke G., Namduri S., DiCarlo E.F., Schneider R., Lane J. Case Report of spontaneous, nonspinal fractures in a multiple mieloma patient on long-term pamidronate and zoledronic acid. HSSJ 2008, 4:123-127.
8. Goddard M.S., Reid K.R., Johnston J.C., Khanuja H.S. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 2009, 32. 10.3928/01477447-20090624-27.
9. Somford M.P., Draijer F.W., Thomassen B.J., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral Fractures of the Femur Diaphysis in a Patient with Rheumatoid Arthritis on Long-term Treatment with Alendronate: Clues to the Mechanism of Increased Bone Fragility. J Bone Miner Res 2009, 24:1736-1740.
10. Capeci C.M., Tejwani N.C. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009, 91:2556-2561.
11. Ali T., Jay R.H. Spontaneous femoral shaft fracture after long-term alendronate. Age Ageing 2009, 38:625-626.
12. Lee J.K. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis 2009, 12:149-154.
13. Sayed-Noor A.S., Sjödén G.O. Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy. Clin Orthop Relat Res 2009, 467:1921-1926.
14. Bamrungsong T., Pongchaiyakul C. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. J Med Assoc Thai 2010, 93:620-624.
15. Cermak K., Shumelinsky F., Alexiou J., Gebhart M.J. Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy. Clin Orthop Relat Res 2010, 468:1991-1996.
16. Atik O.S., Suluova F., Görmeli G., Yildirim A., Ali A.K. Insufficiency femoral fractures in patients undergoing prolonged alendronate therapy. Eklem Hastalik Cerrahisi 2010, 21:56-59.
17. Breglia M.D., Carter J.D. Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol 2010, 16:76-78.
18. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Rao D.S. Unusual mid-shaft fractures during long-term biphosphonate therapy. Clin Endocrinol 2010, 72:161-168.
19. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and biphosphonate therapy. A systematic review of case/case series studies. Bone 2010, 47:169-180.
20. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., et al. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. N Engl J Med 2010, 362:1761-1771.
21. Shane E., Burr D., Ebling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
22. Shane E. Evolving data about subtrochanteric fractures and biphosphonates. N Engl J Med 2010, 362:1825-1827.
23. Salminen S., Pihlajamaki H., Avikainen V., Kyro A., Bostman O. Specific features associated with femoral shaft fractures caused by low energy trauma. J Trauma 1997, 43:117-122.
24. Ekstrom W., Nemeth G., Samnegard E., Dalen N., Tidemark J. Quality of life after a subtrochanteric fracture: A prospective cohort study on 87 elderly patients. Injury 2009, 40:371-376.
25. Daffner R.H., Pavlov H. Stress fractures: current concepts. AJR Am J Roentgenol 1992, 159:245-252.
26. Martin-Hunyadi C., Heitz D., Kaltenbach G., Pfitzenmeyer P., Mourey F., Vogel T., et al. Spontaneous insufficiency fractures of long bones: a prospective epidemiological survey in nursing home subjects. Arch Gerontol Geriatr 2000, 31:207-214.
27. Nieves J.W., Bilezikian J.P., Lane J.M., Einhorn T.A., Wang Y., Steinbuch M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21:399-408.
28. Wang Z., Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and biphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011, 26:553-560.
29. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
30. Dell R., Greene D., Ott S. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. ASBMR 2010 Annual Meeting, Toronto, Canada 2010.
31. Venkatanarasimha N., Miles G., Suresh P. Subtrochanteric femoral insufficiency fractures related to the use of long-term bisphosphonates: a pictorial review. Emerg Radiol 2010, 17:511-515.
32. Porrino J.A., Kohl C.A., Taljanovic M., Rogers L.F. Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. AJR Am J Roentgenol 2010, 194:1061-1064.
33. Visekruna M., Wilson D., McKiernan F.E. Severely supressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93:2948-2952.
34. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
35. Goh S.K., Yang K.Y., Koh J.S., Wong M.K., Chua S.Y., Chua D.T.C., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007, 89:349-353.
36. Spivacow F.R., Sarli M., Butazzoni M. Tratamiento con bifosfonatos y fracturas atípicas. Medicina (B Aires) 2009, 69:612-618.
37. Kwek E.B., Koh J.S., Howe T.S. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008, 359:316-317.
38. Lenart B.A., Lorich D.G., Lane J.M. More on atypical fractures of the femoral diaphysis.Autor reply. N Engl J Med 2008, 359:317-318.
39. Koh J.S., Goh S.K., Png M.A., Kwek E.B., Howe T.S. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?. J Orthop Trauma 2010, 24:75-81.
40. Chan S.S., Rosenberg Z.S., Chan K., Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: Imaging features. AJR 2010, 194:1581-1586.
41. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
42. Isaacs J.D., Shidiak L., Harris I.A., Szomor Z.L. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res 2010, 468:3384-3392.
43. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., Hawker G.A., Gunraj N., Austin P.C., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 23:783-789.
44. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
45. Abrahamsen B., Eiken P., Eastell R. Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
46. Rizzoli R., Akesson K., Bouxsein M., Kanis J.A., Napoli N., Papapoulos S., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Gro*up Report. Osteoporos Int 2011, 22:373-390.